Progenics Pharma (PGNX) Presents Full Phase 2 Data for PSMA ADC in mCRPC
Tweet Send to a Friend
Progenics Pharmaceuticals, Inc., (Nasdaq: PGNX) announced the presentation of the full results from its Phase 2 clinical study of PSMA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
